New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:40 EDTPBMD, CYTX, HART, CAPR, ATHX, CELG, NBS, BLUE, FATEAlliance for Regenerative Medicine to hold a conference
2nd Annual Regen Med Investor Day is being held in New York on March 26 with webcasted company presentations to begin at 8 am; not all company presentations may be webcasted. Webcast Link
News For BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS From The Last 14 Days
Check below for free stories on BLUE;FATE;PBMD;CYTX;HART;CAPR;ATHX;CELG;NBS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
11:20 EDTCELGCelgene added to short term buy list at Deutsche Bank
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Subscribe for More Information
August 25, 2014
12:19 EDTCELGOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTCELGBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 20, 2014
08:02 EDTCELGBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 19, 2014
09:38 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
09:07 EDTCYTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTCYTXBARDA executes contract option with Cytori valued at $12.1M
Subscribe for More Information
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
August 18, 2014
13:31 EDTCYTXCytori Therapeutics appoints Girao CFO to replace Saad
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use